hotspot -WSS

hotspot

author：entertainment 2025-09-27 13:10:42 - browse：1281

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

focus

WSS

BridgeBio heart drug succeeds in pivotal study

House passes resolution saying Israel isn't a 'racist or apartheid state'

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Fauci’s Covid grilling leads GOP to weigh foreign research rules

The nurse manager staffing crisis is hurting patients

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

knowledge

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

23andMe had bad news about my health. I wish a person had delivered it

New Medicare drug pricing powers could soon be upended in court

Hepatitis C has a cure — but many Americans still lack access to it

Heart disease and mental health: A look at cardiac psychology

State Dept. review finds Biden bears some blame for Afghanistan failures

New England Journal of Medicine addresses racist history, slavery

Hepatitis C has a cure — but many Americans still lack access to it

What we know about the American soldier detained in North Korea

leisure time

Biden administration sends mixed signals on US soldier who crossed into North Korea

New Medicare drug pricing powers could soon be upended in court

Why you get paid to donate plasma but not blood

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

Robert Kennedy Jr.'s presidential campaign attracts GOP

What we know about the American soldier detained in North Korea

focus

hotspot

hotspot

hotspot